MALIGNANCY IN MULTINODULAR GOITER-POST THYROIDECTOMY: A PROSPECTIVE STUDY
Fizza Naeem, Sayed Nusrat Raza, Taimoor Ashraf Khan
Pakistan Armed Forces Medical Journal · 2021
doi:10.51253/pafmj.v71i1.4653 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Objective: To find out the frequency and types of malignancy in patients treated surgically for nontoxic multinodular goiter and its correlation in different age groups and gender. Study Design: Cross-sectional study. Place and Duration of Study: Department of ENT, Combined Military Hospital Rawalpindi, from Dec 2018 to Dec 2019. Methodology: A total of 116 patients operated for nontoxic multinodular goiter were included in the study. Demographic details along with pre-op Ultrasonography findings, Fine Needle Aspiration Cytology, thyroid function test results and post-op histopathological reports of the thyroid specimen were entered on pre-designed proforma. Results were analyzed using the Statistical Package for Social Sciences (SPSS) Version 22. Results: Age ranges from 19 to 70 years (mean 43.51 years). Out of 116 cases operated for multinodular goiter, 37 (31.8%) had malignant thyroid lesions (13 males, 24 females). Papillary carcinoma of the thyroid (45.9%) was the commonest malignancy followed by a follicular variant of papillary carcinoma (24.3%). The most common age group with malignancies was 49-58 years. Conclusion: Malignant Thyroid cancers showed a female preponderance and were most common in age group 49-58 years. Papillary carcinoma of thyroid was the commonest tumor. Radical thyroid surgery is a recommended surgical management option for nontoxic Multinodular goiter.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.